BioMarin recently reported key findings from preclinical studies of their investigational, gene therapy Roctavian (valoctocogene roxaparvovec), which was developed for the treatment of adults with severe hemophilia A. The findings were presented at…
Using Math to Understand Bleeding in Hemophilia Patients
Speaker: Karin Leiderman, MD
Did you miss the June 2nd Wednesday Webinar? If so you can listen here to Karin Leiderman, MD discuss Using Math to Understand Bleeding in…
Objective:
Daily administrations of FVIII products are considered useful for providing high FVIII coverage for active patients with hemophilia A. This analysis was performed to determine the daily dose levels required of N8-GP (…
Danger Signals and Inhibitor Development
Speaker: Radoslaw Kaczmarek
Did you miss the June 9th Wednesday Webinar series? If so you can listen here to Redek Kaczmarek, PhD discuss Danger Signals and Inhibitor Development…
The Current Status of Gene Therapy in Hemophilia
Speaker: John Pasi, MB, ChB
Register for the Wednesday Webinar Series
State of the Science Research Summit
Speaker: Leonard A Valentino, MD; Michael Retch, MD
Did you miss the June 23rd Wednesday Webinar on the State of the Science Research Summit? Listen to NHF President and CEO Leonard A…
VWD Guidelines and Shared Decision-making
Speaker: Nathan Connell, MD, MPH; Paula James, MD; Jean Grow, PhD
Did you miss the June 30th Wednesday Webinar series in the new VWD Guidelines and Shared Decision Making? If so…
The inherited bleeding disorders community has seen significant advancements in care, thanks to new therapeutics and technologies, and improved diagnostics. Yet there are still important and persistent gaps in care today, particularly for those with…
NBDF considers the BDRC as an opportunity to address gaps in knowledge that can improve the lives of people affected by inheritable bleeding disorders. We want to ensure that the lived experience drives and influences the research process with…